Diffusion of antibiotics into lung tissue. Critical analysis of the literature;Diffusion pulmonaire des antibiotiques. Analyse critique de la littérature

Annales Francaises d'Anesthesie et de Reanimation

Volumn 20, Issue 7, 2001, Pages 612-630

  Boselli, E ^a   Allaouchiche, B ^a  

^a HÔTEL DIEU   (France)

Author keywords

Antibiotics; Efficiency; Inhibitory quotient; Pulmonary disposition

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFADROXIL; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFPIROME; CEFPODOXIME PROXETIL; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; IMIPENEM; MACROLIDE; PEFLOXACIN; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TICARCILLIN; TIMENTIN; UNINDEXED DRUG;

CALCULATION; DRUG DIFFUSION; DRUG DISPOSITION; DRUG EFFICACY; DRUG TISSUE LEVEL; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG DIFFUSION; LUNG INFECTION; MEDICAL INFORMATION; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; REVIEW;

EID: 0034864120     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0750-7658(01)00439-7     Document Type: Article

References (84)

1. Pulmonary disposition of antimicrobial agents: Methodological considerations
2. Antibiotic pharmacokinetic considerations in pulmonary infections
3. Pulmonary metabolism of foreign compounds: Its role in metabolic activation
4. Antibiotic penetration into lung tissue
5. The site concentrations of antimicrobial agents in the lung
6. Role of β-lactamases in the response of pulmonary infections to amoxycillin/clavulanate
7. Clinical significance of antibiotic tissue penetration
8. Pharmacokinetics of antimicrobial agents in the respiratory tract
9. Intrapulmonary concentrations of antimicrobial agents
10. Antibiotic tissue penetration and its relevance: Models of tissue penetration and their meaning
11. Pharmacokinetics of antibiotics in the lungs
12. Microlavage - A technique for the determination of epithelial lining fluid volume
13. Intracellular pharmacokinetics and localization of antibiotics as predictors of their efficacity against intraphagocyt infections
14. Comparison between penetration of amoxicillin combined with carbocysteine and amoxicillin alone in pathological bronchial secretion and pulmonary tissue
15. Predicting the efficacity of antimicrobial agents in respiratory infections - Is tissue concentration a valid measure?
16. Evaluation of the penetration of ciprofloxacin and amoxicillin into the bronchial mucosa
17. Levels of erythromycin in pulmonary tissue and bronchial mucus compared to those of amoxycillin
18. Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection
19. Concentration of antimicrobials in the pulmonary alveolar epithelial lining
20. Penetration of amoxycillin/clavulanic acid into bronchial mucosa with different dosing regimen
21. Penetration into lung tissue after intravenous administration of amoxycillin/clavulanate
22. The penetration of Augmentin into the pleural fluid
23. Pharmacocinétique des antibiotiques dans les voies respiratoires inférieures. Limites de l'apport de cette information
24. Tissue distribution of Timentin
25. Penetration of piperacillin into bronchial mucosa and sputum
26. A clinical study of transfer of cefiminox and piperacillin into pulmonary tissue
27. Serum and lung tissue concentrations of imipenem
28. Imipenem kinetics in serum, lung tissue and pericardial fluid in patients undergoing thoracotomy
29. Penetration of imipenem-cilastatin into the lung tissue and pericardial fluid of thoracotomized patients
30. The pleural distribution of imipenem/cilastatin sodium
31. Penetration of cefazolin into pleural fluid
32. Penetration of cefuroxime and ceftazidime into human lungs
33. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin and cefuroxime in volunteer subjects
34. Penetration of cefuroxime and doxycycline into the pleural fluid
35. Pulmonary and bronchial kinetics of cefuroxime after a single 500 mg intramuscular injection
36. Penetration of antibiotics into the bronchial mucosa. A review
37. Penetration of antimicrobials in the pulmonary alveolar lining fluid
38. New concepts in the pulmonary disposition of antibiotics
39. Comparative concentration of cefoxitin in human lungs and sera
40. Clinical study on transfer into lung tissue and postoperative prophylactic effect of new cephamycin antibiotics, particularly cefotetan and cefbuperazone
41. Concentration of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens
42. Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients
43. Study on cefotaxime in respiratory surgery: Transfer to lung tissue and kinetics in serum
44. Concentrations of ceftriaxone in serum and lung tissue
45. Distribution of ceftriaxone in human pulmonary and bronchial tissue. Concentrations of ceftriaxone in non-inflamed pulmonary and bronchial tissue and in blood plasma
46. Pharmacokinetics and tissue penetration of a single dose of ceftriaxone (1, 000 milligrams intravenously) for antibiotic prophylaxis in thoracic surgery
47. Pharmacokinetics and tissue penetration of ceftazidime: Studies on lymph, aqueous humor, skin blister, cerebrospinal fluid and pleural fluid
48. Pulmonary penetration of ceftazidime
49. Studies on penetration of cefepime into respiratory tract using broncho-alveolar lavage and sputum
50. The penetration of cefpirome into the potential sites of pulmonary infection
51. Penetration of aminoglycosides in uninfected pleural exudates and in pleural empyemas
52. Tobramycin penetration into epithelial lining fluid of patients with pneumonial
53. Tissue penetration and pulmonary disposition of tobramycin
54. Amikacin: In vitro bacteriological studies, levels in human serum, lung and heart tissue, and clinical results
55. Diffusion de l'amikacine dans les poumons
56. Accumulation of pefloxacin in the lower respiratory tract demonstrated by bronchoalveolar lavage
57. Diffusion of ofloxacin into human lung tissue
58. Bronchial penetration of ofloxacin after single and multiple oral dosage
59. Reproductibility of the measurement of ciprofloxacin concentration in bronchial mucosa
60. Respiratory tract penetration of ciprofloxacin
61. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: Penetration of the bronchial mucosa
62. Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose
63. Penetration of ciprofloxacin into human pleural fluid
64. Penetration of sparfloxacin and ciprofloxacin in alveolar macrophages, epithelial lining fluid and polymorphonuclear leucocytes
65. Intrapulmonary pharmacokinetics of clarythromycin and erythromycin
66. Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibiotic
67. Penetration of clarythromycin into lung tissues from patients undergoing lung resectomy
68. The diffusion of clarythromycin and roxithromycin into nasal mucosa, tonsil and lung in humans
69. The levels of clarythromycin and its 14-hydroxy metabolite in the lung
70. Penetration of clarythromycin into lung tissues from patients undergoing lung resection
71. High and prolonged pulmonary tissue concentration of azithromycin following a single oral dose
72. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses
73. Pulmonary distribution of dirithromycin in patients suffering from acute exacerbation of acute chronic bronchitis
74. Penetration of vancomycin into human lung tissue
75. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients
76. Tissue levels of doxycycline into the human lung and pleura
77. The inhibitory quotient - A method for interpreting minimum inhibitory concentration data
78. Appit, pneumopathies infectieuses
79. Appit, pleurésies
80. Sensibilité et résistance des souches - Quotients inhibiteurs
81. Conférence de consensus. Quelle doit être l'antibiothérapie de première intention des pneumonies aiguës communautaires? Quelle doit être sa réévaluation en cas d'échec, compte tenu de l'évolution des agents responsables, des résistances du pneumocoque, et cela justifie-t-il des associations?
82. Infections pulmonaires nosocomiales